Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries

• Status: Not yet recruiting
• Trial end date: 2024-07-15
• Target enrollment: 0
• Participant gender: All

Summary

A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role. This review also showed a significant reduction in the rate of gross motor dysfunction in early childhood. Early Preterm birth (< 34+0 weeks) and very low birthweight (< 1,500 g) are the principal risk factors for cerebral palsy. Multiple pregnancy accounts for over 10% of preterm births and has a higher incidence of cerebral palsy than singleton pregnancy (twins have 7 times and triplets 47 times the risk of cerebral palsy compared with singletons).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

1. Women at risk of preterm birth who are between 24+0 and 33+6 weeks of gestation.

2. When early preterm birth is planned or expected within 24 h, regardless of:

• Plurality or parity

• Reason for the risks of preterm birth

• Anticipated mode of birth

• Whether antenatal corticosteroids have been given or not

Exclusion Criteria:

• Women with known Hypersensitivity to magnesium

• Caution regarding dosage for patients with renal impairment

• Preterm delivery after 34 weeks